New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis

By sjmartinez • August 28, 2022

Feng W, Xiao Y, Zhao C, Zhang Z, Liu W, Ma J, Ganz T, Zhang J, Liu S. New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis. Adv Sci (Weinh). 2022 Aug 28:e2202679. doi: 10.1002/advs.202202679. Epub ahead of print. PMID: 36031399.

Tags: deferric amine compound, Ferroptosis, Hematology/Oncology, iron chelator, iron overload, liver injury, Publications, Pulmonary, Critical Care & Sleep Medicine

Related Posts

Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib

Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman[...]

ZNFX1 functions as a master regulator of epigenetically induced pathogen mimicry and inflammasome signaling in cancer

Stojanovic L, Abbotts R, Tripathi K, Coon CM, Rajendran S, Abbasi Farid E, Hostetter G, Guarnieri JW, Wallace DC, Liu S, Wan J, Calendo G,[...]

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka[...]